NeuroMab™ Anti-Alpha Synuclein BBB Shuttle Antibody, Clone NR52P
- Host Species:
- Rabbit
- Species Reactivity:
- Human
- Applications:
- DB; ELISA; FC; IHC; In Vitro; Cyt; In Vivo
To download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.
Lot Number
SPECIFIC INQUIRY
Description
Notes: The BBB antibody is made-to order and available in a customized format. Please don't hesitate contact us for more details.
Species Reactivity
Clonality
Host Species
Clone Number
Applications
Storage
Research Use Only
Target
Official Name
Full Name
Alternative Names
Fig.1 Alpha-synuclein staining in brain stem of an alpha-synuclein[A30P]-transgenic mouse.
Fresh frozen 10 μm sagittal brain sections; 40× magnification; all images at identical illumination conditions; arrowheads indicate Lewy neurite-like inclusions.
Fig.2 Staining of antibodies 0017 and 0018 in human brain cortex of a Parkinson's Disease patient.
(A), an Alzheimer's Disease patient with Parkinson's Disease comorbidity (B) and progressive supranuclear palsy (PSP, tauopathy) (C); arrow: Lewy-body like inclusions; arrowhead: Lewy neurite-like inclusions.
Fig.3 Cellular toxicity of conditioned media from recombinant alpha-synuclein from SHSY5Y cells on LUHMES cells.
(A), an Alzheimer's Disease patient with Parkinson's Disease comorbidity (B) and progressive supranuclear palsy (PSP, tauopathy) (C); arrow: Lewy-body like inclusions; arrowhead: Lewy neurite-like inclusions.
Fig.4 The antibody is able to immunodeplete alpha-synuclein oligomers from extracellular media and thereby these antibodies reduce toxicity of alpha-synuclein oligomers.
(A), an Alzheimer's Disease patient with Parkinson's Disease comorbidity (B) and progressive supranuclear palsy (PSP, tauopathy) (C); arrow: Lewy-body like inclusions; arrowhead: Lewy neurite-like inclusions.
Fig.5 Labeling of brain alpha-synuclein pathology, vasculature, and parenchyma in alpha-synuclein mutant A30P transgenic mice upon acute peripheral injection of an anti-alpha synuclein-antibody-blood-brain-barrier shuttle module conjugate.
(A), an Alzheimer's Disease patient with Parkinson's Disease comorbidity (B) and progressive supranuclear palsy (PSP, tauopathy) (C); arrow: Lewy-body like inclusions; arrowhead: Lewy neurite-like inclusions.
Fig.6 Confocal microscopy analysis of immunohistochemically analyzed cryosections of Parkinson's Disease patient's brain sections (identical setting for all images).
(A) antibody 0017, (B) antibody 0018.
Fig.7 Binding of monomeric (N-terminally free (1) and N-terminally His-tagged (2)) and dimeric (3) alpha-synuclein to antibody 0018.
The results shown are a titration of 5 concentrations.
1: monomer, free N-terminus, 4.2 mg/mL, never thawed;
2: monomer, His-tagged N-terminus, 4.8 mg/mL;
3: dimer, free N-terminus, 1.6 mg/mL.
